Arjo AB (FRA:A39) Dividends Received

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:A39 Arjo AB FRA:A39
74 GF Score
Price €2.37
GF Value €3.13
Valuation Modestly Undervalued
! 5 Warning Signs
View Full Analysis

What is Arjo AB Dividends Received?

Dividends Received only applicable to companies reporting Cash Flow from Operations in direct method.

FRA:A39
74GF Score
Arjo AB FRA:A39
Dividends Received is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Arjo AB (FRA:A39) Overvalued in 2026?

Based on GuruFocus' analysis, Arjo AB stock appears to be undervalued. The current stock price of €2.37 is trading 24.2% below its estimated GF Value™ of €3.13. GuruFocus considers Arjo AB to be Modestly Undervalued.

Key valuation signals for FRA:A39:

  • Dividends Received:
  • GF Value™: €3.13 vs. price of €2.37 (24.2% below fair value)
  • GF Score™: 74/100 with 5 warning signs

No single metric tells the full story. See the FRA:A39 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Arjo AB Business Description

Address Hans Michelsensgatan 10, Box 48, Malmo, SWE, SE-201 20
Arjo AB is a supplier of medical devices, services, and solutions in Sweden. It serves its services to private and public institutions with acute care and long-term care. The company's offering includes products and solutions for patient handling, hygiene, disinfection, medical beds, therapeutic surfaces, venous thromboembolism (VTE) prevention and diagnostics. The company includes segments: Global Sales, North America, Diagnostics.
74GF Score

Get the complete analysis for FRA:A39

Dividends Received is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€2.37
Price
€3.13
GF Value